Selexis SA and NexImmune Inc.: Selexis and NexImmune Sign Se

Agreement supports the development of molecules targeting acute myeloid leukemia, multiple myeloma, human papilloma virus (HPV) associated tumors, and additional human leukocyte antigens (HLAs) that

Related Keywords

Maria Pilar Gim , Mathias Oelke , Markw Womack , Mike Beyer , Company Inquiries For Selexis , Neximmune Inc , Life Sciences , Nasdaq , Sam Brown Inc , Chief Executive Officer , Neximmune Chief Scientific Officer , Artificial Immune Modulation , Pilar Gim , Marketing Director , Selexis , Neximmune , Sign , Service , Agreement , Advance , Multiple , Mmunotherapies , Targeting , Mare , Cancers , Autoimmune , Disorders ,